Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours

被引:37
|
作者
Tsang, V. H. M. [1 ,2 ]
Dwight, T. [1 ]
Benn, D. E. [1 ]
Meyer-Rochow, G. Y. [1 ,3 ]
Gill, A. J. [4 ,5 ]
Sywak, M. [6 ]
Sidhu, S. [1 ,6 ]
Veivers, D. [7 ,8 ]
Sue, C. M. [8 ,9 ]
Robinson, B. G. [1 ,2 ]
Clifton-Bligh, R. J. [1 ,2 ]
Parker, N. R. [10 ]
机构
[1] Univ Sydney, Royal N Shore Hosp, Cancer Genet Lab, Kolling Inst Med Res, Sydney, NSW 2065, Australia
[2] Univ Sydney, Royal N Shore Hosp, Dept Endocrinol, Sydney, NSW 2065, Australia
[3] Univ Auckland, Waikato Clin Sch, Fac Med & Hlth Sci, Dept Surg, Auckland 1142, New Zealand
[4] Univ Sydney, Royal N Shore Hosp, Dept Anat Pathol, Sydney, NSW 2065, Australia
[5] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Canc Diag & Oncol Grp, Sydney, NSW 2065, Australia
[6] Univ Sydney, Royal N Shore Hosp, Dept Endocrine & Oncol Surg, Sydney, NSW 2065, Australia
[7] Univ Sydney, Royal N Shore Hosp, Neurogenet Res Lab, Kolling Inst Med Res, Sydney, NSW 2065, Australia
[8] Univ Sydney, Royal N Shore Hosp, Dept ENT Surg, Sydney, NSW 2065, Australia
[9] Univ Sydney, Royal N Shore Hosp, Dept Neurol, Sydney, NSW 2065, Australia
[10] Univ Sydney, Royal N Shore Hosp, Bill Walsh Translat Canc Res Lab, Kolling Inst Med Res, Sydney, NSW 2065, Australia
关键词
pheochromocytoma; paraganglioma; gastrointestinal stromal tumour; succinate dehydrogenase; miR-210; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; SUCCINATE-DEHYDROGENASE; MALIGNANT PHEOCHROMOCYTOMAS; GERMLINE MUTATIONS; RENAL TUMORS; COMPLEX-II; GENE; EXPRESSION; SUSCEPTIBILITY; BENIGN;
D O I
10.1530/ERC-13-0519
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
miR-210 is a key regulator of response to hypoxia. Pheochromocytomas (PCs) and paragangliomas (PGLs) with germline SDHx or VHL mutations have pseudohypoxic gene expression signatures. We hypothesised that PC/PGLs containing SDHx or VHL mutations, and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours (GISTs), would overexpress miR-210 relative to non-SDH or -VHL-mutated counterparts. miR-210 was analysed by quantitative PCR in i) 39 PC/PGLs, according to genotype (one SDHA, five SDHB, seven VHL, three NF1, seven RET, 15 sporadic, one unknown) and pathology (18 benign, eight atypical, 11 malignant, two unknown); ii) 18 GISTs, according to SDHB immunoreactivity (nine SDH-deficient and nine SDH-proficient) and iii) two novel SDHB-mutant neurosphere cell lines. miR-210 was higher in SDHx-or VHL-mutated PC/PGLs (7.6-fold) compared with tumours without SDHx or VHL mutations (P=0.0016). miR-210 was higher inmalignant than in unequivocally benign PC/PGLs (P=0.05), but significance was lost when benign and atypical tumours were combined (P=0.08). In multivariate analysis, elevated miR-210 was significantly associated with SDHx or VHL mutation, but not with malignancy. In GISTs, miR-210 was higher in SDH-deficient (median 2.58) compared with SDH proficient tumours (median 0.60; P=0.0078). miR-210 was higher in patient-derived neurosphere cell lines containing SDHB mutations (6.5-fold increase) compared with normal controls, in normoxic conditions (P<0.01). Furthermore, siRNA-knockdown of SDHB in HEK293 cells increased miR-210 by 2.7-fold (P=0.001) under normoxia. Overall, our results suggest that SDH deficiency in PC, PGL and GISTs induces miR-210 expression and substantiates the role of aberrant hypoxic-type cellular responses in the development of these tumours.
引用
收藏
页码:415 / 426
页数:12
相关论文
共 8 条
  • [1] Clinical evaluation of serum succinate levels as a new biomarker in SDH-related paragangliomas and pheochromocytomas
    Lamy, C.
    Tissot, H.
    Faron, M.
    Baudin, E.
    Leboulleux, S.
    Paci, A.
    Hadoux, J.
    Broutin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S773 - S774
  • [2] Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia
    Tang, Xiaoqiong
    Chen, Liping
    Yan, Xinyu
    Li, Yuanjie
    Xiong, Yuanlin
    Zhou, Xiaohui
    MEDICAL SCIENCE MONITOR, 2015, 21
  • [3] Overexpression of mir-135b and mir-210 in mesenchymal stromal cells for the enrichment of extracellular vesicles with angiogenic factors
    Freitas Vieira, Juliana Maira
    Zamproni, Laura Nicoleti
    Wendt, Camila H. C.
    de Miranda, Kildare Rocha
    Lindoso, Rafael Soares
    Han, Sang Won
    PLOS ONE, 2022, 17 (08):
  • [4] ENRICHMENT OF EXTRACELLULAR VESICLES WITH ANGIOGENIC FACTORS BY OVEREXPRESSION OF MIR-210 AND MIR-135B IN MESENCHYMAL STROMAL CELLS
    Vieira, J. M. F.
    Zamproni, L. N.
    Wendt, C. H. C.
    Miranda, K. R.
    Lindoso, R. S.
    Han, S. W.
    CYTOTHERAPY, 2022, 24 (10) : S1 - S2
  • [5] Effect of Overexpression of miR-135b and miR-210 on Mesenchymal Stromal Cells on the Production of Extracellular Vesicles with Angiogenic Factors
    Vieira, Juliana M. F.
    Zamproni, Laura N.
    Lindoso, Rafael S.
    Han, Sang W.
    MOLECULAR THERAPY, 2021, 29 (04) : 221 - 222
  • [6] Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer – a multicenter (in situ hybridization) study
    Sigve Andersen
    Elin Richardsen
    Line Moi
    Tom Donnem
    Yngve Nordby
    Nora Ness
    Marte Eilertsen Holman
    Roy M. Bremnes
    Lill-Tove Busund
    Scientific Reports, 6
  • [7] Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study
    Andersen, Sigve
    Richardsen, Elin
    Moi, Line
    Donnem, Tom
    Nordby, Yngve
    Ness, Nora
    Holman, Marte Eilertsen
    Bremnes, Roy M.
    Busund, Lill-Tove
    SCIENTIFIC REPORTS, 2016, 6
  • [8] Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib
    Verboom, Michiel C.
    Kloth, Jacqueline S. L.
    Swen, Jesse J.
    van der Straaten, Tahar
    Bovee, Judith V. M. G.
    Sleijfer, Stefan
    Reyners, Anna K. L.
    Mathijssen, Ron H. J.
    Guchelaar, Henk-Jan
    Steeghs, Neeltje
    Gelderblom, Hans
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 226 - 232